摘要
目的:探讨血清核因子E2相关因子2(Nrf2)、转化生长因子结合蛋白2(LTBP2)、血小板内皮细胞黏附分子1(PECAM1)与非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)靶向治疗反应性关系及意义。方法:选取我院2021年1月—2023年1月收治的95例NSCLC患者为研究对象,根据EGFR靶向治疗3个月后的治疗反应性分为有效组(54例)、无效组(41例)。比较2组治疗前及治疗1个月、2个月后血清Nrf2、LTBP2、PECAM1水平,分析治疗1个月、2个月后血清Nrf2、LTBP2、PECAM1水平与NSCLC患者EGFR靶向治疗反应性相关性,偏回归分析治疗无效的影响因素,受试者工作特征曲线(ROC)分析治疗1个月、2个月后血清Nrf2、LTBP2、PECAM1水平联合检测对NSCLC患者EGFR靶向治疗效果的预测价值。结果:治疗1个月、2个月后无效组血清Nrf2、LTBP2、PECAM1水平均高于有效组(P<0.05);相关性分析发现,治疗1个月、2个月后血清Nrf2、LTBP2、PECAM1水平与治疗反应性均呈负相关(P<0.05);Logistic回归分析发现,治疗1个月、2个月后血清Nrf2、LTBP2、PECAM1水平为NSCLC患者EGFR靶向治疗效果的影响因素(P<0.05);ROC曲线分析发现,治疗1个月、2个月后血清Nrf2、LTBP2、PECAM1水平联合预测治疗无效的曲线下面积(AUC)分别为0.761、0.816,最佳预测敏感度、特异度分别为(85.37%、66.67%)、(92.68%、70.37%),高于单一指标预测(P<0.05)。结论:血清Nrf2、LTBP2、PECAM1水平与NSCLC患者EGFR靶向治疗反应性密切相关,并在预测治疗效果方面具有较高效能。
Objective:To investigate the relationship and significance between serum nuclear factor E2-related factor 2(Nrf2),transforming growth factor binding protein 2(LTBP2),platelet endothelial cell adhesion molecule 1(PECAM1)and the epidermal growth factor receptor(EGFR)targeted therapy response in Non-small-cell lung cancer(NSCLC)patients.Methods:95 patients with NSCLC admitted to our hospital from January 2021 to January 2023 were selected as the study objects.According to the treatment reactivity after 3 months of EGFR-targeted therapy,they were divided into effective group(54 cases)and ineffective group(41 cases).Serum Nrf2,LTBP2 and PECAM1 levels were compared between the two groups before treatment,1 month and 2 months after treatment,and the correlation between serum Nrf2,LTBP2 and PECAM1 levels and the reactivity of EGFR targeted therapy in NSCLC patients was analyzed,and the influential factors of treatment ineffective were analyzed by partial regression.Receiver operating characteristic curve(ROC)was used to analyze the predictive value of combined detection of serum Nrf2,LTBP2 and PECAM1 levels in NSCLC patients after 1 month and 2 months of treatment.Results:After 1 month and 2 months of treatment,the serum Nrf2,LTBP2 and PECAM1 levels in the ineffective group were higher than those in the effective group(P<0.05).Correlation analysis showed that serum Nrf2,LTBP2 and PECAM1 levels were negatively correlated with treatment reactivity after 1 month and 2 months of treatment(P<0.05).Logistic regression analysis showed that the levels of serum Nrf2,LTBP2 and PECAM1 after 1 month and 2 months of treatment were the influential factors for the efficacy of EGFR-targeted therapy in NSCLC patients(P<0.05).ROC curve analysis showed that the area under the curve(AUC)of serum Nrf2,LTBP2 and PECAM1 combined to predict treatment failure after 1 month and 2 months of treatment were 0.761 and 0.816,respectively.The best prediction sensitivity and specificity were(85.37%,66.67%),(92.68%,70.37%),respectively,which were higher than that of single index prediction(P<0.05).Conclusion:Serum Nrf2,LTBP2 and PECAM1 levels are closely related to EGFR-targeted therapy reactivity in NSCLC patients,and have high efficacy in predicting treatment effect.
作者
李旭东
朱东全
姚凤佳
LI Xudong;ZHU Dongquan;YAO Fengjia(Department of Respiratory and Critical Care Medicine,Zhengzhou Third People’s Hospital,Zhengzhou City,He’nan Province 450000)
出处
《医学理论与实践》
2024年第6期905-907,904,共4页
The Journal of Medical Theory and Practice
关键词
非小细胞肺癌
表皮生长因子受体靶向治疗
治疗反应性
核因子E2相关因子2
转化生长因子结合蛋白2
血小板内皮细胞黏附分子1
Non-small cell lung cancer
Epidermal growth factor receptor targeting therapy
Therapeutic responsiveness
Nuclear factor E2 related factor 2
Transforming growth factor binding protein 2
Platelet endothelial cell adhesion molecules 1
